MCID: KRT005
MIFTS: 49

Keratoacanthoma

Categories: Cancer diseases, Eye diseases, Skin diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Keratoacanthoma

MalaCards integrated aliases for Keratoacanthoma:

Name: Keratoacanthoma 12 76 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3149
MeSH 44 D007636
NCIt 50 C3146
UMLS 73 C0022572

Summaries for Keratoacanthoma

MalaCards based summary : Keratoacanthoma is related to nodular malignant melanoma and actinic keratosis, and has symptoms including exanthema and pruritus. An important gene associated with Keratoacanthoma is MSH2 (MutS Homolog 2), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Azathioprine and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and lung, and related phenotypes are digestive/alimentary and integument

Wikipedia : 76 Keratoacanthoma (KA) is a common low-grade (unlikely to metastasize or invade) skin tumour that is... more...

Related Diseases for Keratoacanthoma

Diseases in the Keratoacanthoma family:

Familial Keratoacanthoma

Diseases related to Keratoacanthoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Related Disease Score Top Affiliating Genes
1 nodular malignant melanoma 29.5 CDKN1A DSG1
2 actinic keratosis 29.5 FLG KRT17 TP53
3 keratosis 29.4 DSG1 FLG KRT10
4 steatocystoma multiplex 29.3 KRT10 KRT16 KRT17
5 bowen's disease 29.2 KRT10 KRT16 KRT17 MKI67
6 papilloma 28.6 CDKN1A FLG KRT10 TP53
7 discoid lupus erythematosus 28.5 FLG GZMB KRT10 KRT16
8 basal cell carcinoma 28.2 CDKN1A KRT10 KRT16 KRT17 MKI67 TP53
9 lichen planus 28.1 FLG GZMB KRT10 KRT16 TP53
10 psoriasis 28.1 FLG KRT10 KRT16 KRT17
11 generalized eruptive keratoacanthoma 12.1
12 familial keratoacanthoma 12.1
13 muir-torre syndrome 11.9
14 vulvar keratoacanthoma-like carcinoma 11.9
15 multiple self-healing squamous epithelioma 11.7
16 palmoplantar carcinoma, multiple self-healing 11.1
17 brain ependymoma 10.8 MKI67 TP53
18 spitz nevus 10.8 MKI67 TP53
19 lip cancer 10.8 MSH2 TP53
20 oral leukoplakia 10.7 MKI67 TP53
21 lichen sclerosus 10.7 GZMB TP53
22 adenosarcoma 10.7 MKI67 TP53
23 soft tissue sarcoma 10.7 MKI67 TP53
24 cervix uteri carcinoma in situ 10.7 KRT17 TP53
25 squamous cell carcinoma 10.7
26 breast squamous cell carcinoma 10.7 KRT10 TP53
27 embryonal sarcoma 10.6 MKI67 TP53
28 basal cell carcinoma, infundibulocystic 10.6 KRT10 KRT17
29 large cell acanthoma 10.6 KRT10 KRT17
30 inverted papilloma 10.6 MKI67 TP53
31 cerebral primitive neuroectodermal tumor 10.6 MSH2 TP53
32 basaloid squamous cell carcinoma 10.6 KRT17 TP53
33 hidradenocarcinoma 10.6 MKI67 TP53
34 invasive bladder transitional cell carcinoma 10.5 CDKN1A TP53
35 bladder transitional cell papilloma 10.5 CDKN1A TP53
36 atypical follicular adenoma 10.5 CDKN1A TP53
37 appendix carcinoid tumor 10.5 MLH1 MSH2
38 adenosquamous colon carcinoma 10.5 MLH1 MSH2
39 sebaceous adenoma 10.5 MLH1 MSH2
40 lower lip cancer 10.5 MLH1 MSH2
41 striate palmoplantar keratoderma 10.5 DSG1 KRT10
42 anal fistula 10.5 MLH1 MSH2
43 necrotizing sialometaplasia 10.5 GZMB MKI67 TP53
44 anal squamous cell carcinoma 10.5 MLH1 TP53
45 suppressor of tumorigenicity 3 10.4 CDKN1A TP53
46 richter's syndrome 10.4 MLH1 TP53
47 melanocytic nevus syndrome, congenital 10.4 MLH1 MSH2
48 childhood kidney cell carcinoma 10.4 MLH1 MSH2
49 pachyonychia congenita 2 10.3 KRT16 KRT17
50 tinea corporis 10.3 KRT16 KRT17

Graphical network of the top 20 diseases related to Keratoacanthoma:



Diseases related to Keratoacanthoma

Symptoms & Phenotypes for Keratoacanthoma

UMLS symptoms related to Keratoacanthoma:


exanthema, pruritus

MGI Mouse Phenotypes related to Keratoacanthoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 CDKN1A KRT16 KRT17 MLH1 MSH2 TP53
2 integument MP:0010771 9.17 CDKN1A DSG1 KRT16 KRT17 MLH1 MSH2

Drugs & Therapeutics for Keratoacanthoma

Drugs for Keratoacanthoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Everolimus Approved Phase 4 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
5
Mycophenolic acid Approved Phase 4 24280-93-1 446541
6
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
8 Cyclosporins Phase 4
9 Anti-Bacterial Agents Phase 4
10 Antibiotics, Antitubercular Phase 4
11 Antifungal Agents Phase 4
12 Anti-Infective Agents Phase 4
13 Calcineurin Inhibitors Phase 4
14 Immunosuppressive Agents Phase 4
15
Dabrafenib Approved, Investigational Phase 3,Phase 2 1195765-45-7 44462760 44516822
16
Trametinib Approved Phase 3,Phase 2 871700-17-3 11707110
17 Protein Kinase Inhibitors Phase 3,Phase 2
18
nivolumab Approved Phase 2 946414-94-4
19 Antibodies Phase 2
20 Antibodies, Monoclonal Phase 2
21 Immunoglobulins Phase 2
22
Sorafenib Approved, Investigational 284461-73-0 216239 406563
23
Methotrexate Approved 1959-05-2, 59-05-2 126941
24
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
25
Niacin Approved, Investigational, Nutraceutical 59-67-6 938
26
Nicotinamide Approved, Investigational, Nutraceutical 98-92-0 936
27 Micronutrients
28 Nicotinic Acids
29 Trace Elements
30 Vitamin B Complex
31 Vitamins
32 Folate Nutraceutical
33 Vitamin B3 Nutraceutical
34 Vitamin B9 Nutraceutical

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
2 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Active, not recruiting NCT01584648 Phase 3 dabrafenib;dabrafenib plus trametinib placebo;Trametinib
3 Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib Completed NCT02314143 Phase 2 Dabrafenib;Trametinib
4 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
5 A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma Withdrawn NCT02068079 Phase 1 Vemurafenib and Trientine
6 Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old Recruiting NCT03155217
7 Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Recruiting NCT02185560 Sorafenib (Nexavar, BAY43-9006)
8 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis Recruiting NCT01617018

Search NIH Clinical Center for Keratoacanthoma

Cochrane evidence based reviews: keratoacanthoma

Genetic Tests for Keratoacanthoma

Anatomical Context for Keratoacanthoma

MalaCards organs/tissues related to Keratoacanthoma:

41
Skin, Thyroid, Lung, Colon, Bone, Cervix, Myeloid

Publications for Keratoacanthoma

Articles related to Keratoacanthoma:

(show top 50) (show all 649)
# Title Authors Year
1
Successful Treatment of a Keratoacanthoma with Electrochemotherapy: A Case Report. ( 29368221 )
2018
2
A Multiple Recurrent Keratoacanthoma of the Lower Leg After Repeated Wide-Excision and Mohs Micrographic Surgery. ( 29953419 )
2018
3
Solitary Palmar Keratoacanthoma: Case Report. ( 29770284 )
2018
4
Topical aminolevulinic acid-photodynamic therapy in the treatment of keratoacanthoma: a case report. ( 29913213 )
2018
5
Topical Imiquimod 5% as a Treatment Option in Solitary Facial Keratoacanthoma. ( 29610614 )
2018
6
Generalized eruptive keratoacanthoma with vitiligo followed by the development of prurigo nodularis: A case report and published work review. ( 29058335 )
2018
7
Keratoacanthoma ( 29763106 )
2018
8
Cutaneous intravascular CD30+ T-cell pseudolymphoma occurring in a regressing keratoacanthoma. ( 29369392 )
2018
9
Multiple keratoacanthoma and oral lichen planus successfully treated with systemic retinoids and review of multiple keratoacanthoma associated with lichen planus. ( 29577263 )
2018
10
KERATOACANTHOMA OF THE UPPER LIP: REVIEW OF THE LITERATURE AND REPORT OF CASE WITH CENTRAL UPPER LIP RECONSTRUCTION. ( 29578429 )
2018
11
Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use. ( 28584672 )
2017
12
Keratoacanthoma of the lip: A case report with emphasis on histogenesis. ( 28479697 )
2017
13
Fine and Benign, Until It Becomes Malignant: The Enigmatic Keratoacanthoma. ( 28705282 )
2017
14
Use of topical ephedrine and naphazoline in the treatment of a keratoacanthoma: two case reports. ( 28712267 )
2017
15
Advances in histopathological diagnosis of keratoacanthoma. ( 28256761 )
2017
16
Eruptive Keratoacanthoma-Like Discoid Lupus Erythematosus. ( 28816744 )
2017
17
Use of photodynamic therapy and acitretin in generalized eruptive keratoacanthoma of Grzybowski. ( 28948204 )
2017
18
Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. ( 28501937 )
2017
19
Keratoacanthoma Centrifugum Marginatum: Response to Acitretin. ( 28270315 )
2017
20
Keratoacanthoma management: results of a survey of UK dermatologists and surgeons. ( 28758190 )
2017
21
Calcified Keratoacanthoma with Tumoral Calcinosis in a 10-year-old Boy: A mere Co-incidence? ( 29263542 )
2017
22
A Case of Exophytic Pilomatricoma Clinically Resembling Keratoacanthoma. ( 28392667 )
2017
23
Multiple keratoacanthoma centrifugum marginatum in a young boy, and review of the literature. ( 28543888 )
2017
24
Multiple keratoacanthoma centrifugum marginatum associated with juvenile idiopathic arthritis and persistent corneal epithelial defect: an unusual case. ( 28906090 )
2017
25
Complete regression of keratoacanthoma with topical tazarotene gel 0.1%: therapeutic and pathophysiological perspectives. ( 28895378 )
2017
26
Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient. ( 27805257 )
2017
27
Keratoacanthoma-like dermatofibroma: A dermoscopic challenge. ( 28087033 )
2017
28
Cytokeratin 17 and Ki-67: Immunohistochemical markers for the differential diagnosis of keratoacanthoma and squamous cell carcinoma. ( 28454431 )
2017
29
Complete regression of crateriform verruca after partial biopsy: Another type of epithelial crateriform tumor or a subtype of keratoacanthoma? ( 29235666 )
2017
30
Keratoacanthoma-Like Growths of Incontinentia Pigmenti Successfully Treated with Intralesional Methotrexate. ( 28414858 )
2017
31
Keratoacanthoma en plaque/nodule: A brief report of the clinicopathological features of five cases. ( 28332728 )
2017
32
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling. ( 28439948 )
2017
33
Keratoacanthoma centrifugum marginatum: an unusual clinical and histopathological diagnostic pitfall. ( 28730244 )
2017
34
Relationship between Human Papilloma Virus and Subungual Keratoacanthoma: Two Case Reports and the Outcomes of Surgical Treatment. ( 28232913 )
2017
35
Subungual Keratoacanthoma in a Patient With Yellow Nail Syndrome. ( 27158885 )
2016
36
Keratoacanthoma of the conjunctiva in a young patient. ( 27463634 )
2016
37
Distal Digital Keratoacanthoma in Patients With Incontinentia Pigmenti. ( 26614487 )
2016
38
Human polyomavirus DNA detection in keratoacanthoma and Spitz naevus: no evidence for a causal role. ( 27993945 )
2016
39
Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma. ( 26782292 )
2016
40
The distinction of keratoacanthoma from various types of squamous cell carcinoma with crateriform architecture. ( 27670127 )
2016
41
Giant keratoacanthoma of the lower lip: case report and review of the published literature. ( 26742162 )
2016
42
Clues in DeRmoscopy: Dermoscopy of keratoacanthoma. ( 27528474 )
2016
43
Keratoacanthoma Shares Driver Mutations with Cutaneous Squamous Cell Carcinoma. ( 27283355 )
2016
44
Keratoacanthoma (KA): An update and review. ( 26853179 )
2016
45
"Nevoid Eruptive Keratoacanthoma" - Yet Another Atypical Manifestation of Generalized Keratoacanthoma. ( 26955113 )
2016
46
Cutaneous Epithelial Lesions Induced by N-Methyl-N-nitrosourea in Male Sprague-Dawley Rats: A Possible Animal Model for Human Keratoacanthoma. ( 26722034 )
2016
47
Keratoacanthoma centrifugum marginatum: A diagnostic and therapeutic challenge. ( 27274538 )
2016
48
Tp53/p53 status in keratoacanthomas. ( 27020606 )
2016
49
Sonographic features of keratoacanthoma. May ultrasound be a useful tool to differentiate it from squamous cell carcinoma? ( 26681149 )
2016
50
Histopathological diagnosis of epithelial crateriform tumors: Keratoacanthoma and other epithelial crateriform tumors. ( 27076258 )
2016

Variations for Keratoacanthoma

Expression for Keratoacanthoma

Search GEO for disease gene expression data for Keratoacanthoma.

Pathways for Keratoacanthoma

Pathways related to Keratoacanthoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.6 CDKN1A MLH1 MSH2 TP53
2 12.55 CDKN1A MLH1 MSH2 TP53
3 12.02 CDKN1A MKI67 MLH1 MSH2 TP53
4 11.98 CDKN1A GZMB TP53
5 11.89 CDKN1A MLH1 MSH2 TP53
6
Show member pathways
11.81 DSG1 FLG KRT10 KRT16 KRT17
7 11.68 CDKN1A MLH1 MSH2 TP53
8 11.6 CDKN1A RBP1 TP53
9 11.55 CDKN1A KRT17 TP53
10 11.24 CDKN1A MSH2 TP53
11
Show member pathways
11.1 MLH1 MSH2 TP53
12 11.07 CDKN1A TP53
13 11.01 MLH1 MSH2
14
Show member pathways
10.85 CDKN1A TP53
15 10.79 CDKN1A MLH1 MSH2 TP53
16 10.57 CDKN1A TP53
17
Show member pathways
10.34 CDKN1A TP53

GO Terms for Keratoacanthoma

Cellular components related to Keratoacanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.91 CDKN1A DSG1 FLG GZMB KRT10 KRT16
2 condensed chromosome GO:0000793 9.32 MKI67 MLH1
3 mismatch repair complex GO:0032300 9.16 MLH1 MSH2
4 cornified envelope GO:0001533 9.13 DSG1 FLG KRT10
5 intermediate filament GO:0005882 8.92 FLG KRT10 KRT16 KRT17

Biological processes related to Keratoacanthoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.88 CDKN1A MLH1 MSH2 TP53
2 cell cycle arrest GO:0007050 9.74 CDKN1A MSH2 TP53
3 epidermis development GO:0008544 9.7 FLG KRT16 KRT17
4 keratinocyte differentiation GO:0030216 9.63 FLG KRT10 KRT16
5 mismatch repair GO:0006298 9.62 MLH1 MSH2
6 cellular response to ionizing radiation GO:0071479 9.62 CDKN1A TP53
7 keratinization GO:0031424 9.62 DSG1 KRT10 KRT16 KRT17
8 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.61 GZMB TP53
9 intrinsic apoptotic signaling pathway GO:0097193 9.61 CDKN1A TP53
10 positive regulation of reactive oxygen species metabolic process GO:2000379 9.6 CDKN1A TP53
11 cellular response to gamma radiation GO:0071480 9.59 CDKN1A TP53
12 establishment of skin barrier GO:0061436 9.58 FLG KRT16
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.56 CDKN1A TP53
14 somatic hypermutation of immunoglobulin genes GO:0016446 9.55 MLH1 MSH2
15 isotype switching GO:0045190 9.54 MLH1 MSH2
16 replicative senescence GO:0090399 9.51 CDKN1A TP53
17 determination of adult lifespan GO:0008340 9.49 MSH2 TP53
18 positive regulation of isotype switching to IgG isotypes GO:0048304 9.48 MLH1 MSH2
19 signal transduction by p53 class mediator GO:0072331 9.43 CDKN1A TP53
20 positive regulation of isotype switching to IgA isotypes GO:0048298 9.4 MLH1 MSH2
21 somatic recombination of immunoglobulin gene segments GO:0016447 9.37 MLH1 MSH2
22 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.33 CDKN1A MSH2 TP53
23 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.26 MLH1 MSH2
24 response to X-ray GO:0010165 9.13 CDKN1A MSH2 TP53
25 cornification GO:0070268 9.02 DSG1 FLG KRT10 KRT16 KRT17

Molecular functions related to Keratoacanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of epidermis GO:0030280 9.26 FLG KRT10
2 structural molecule activity GO:0005198 9.26 FLG KRT10 KRT16 KRT17
3 mismatched DNA binding GO:0030983 9.16 MLH1 MSH2
4 guanine/thymine mispair binding GO:0032137 8.62 MLH1 MSH2

Sources for Keratoacanthoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....